GlaxoSmithKline Plc has announced an agreement to fully acquire Cellzome, a specialist in proteomics technology, for £61 million in cash. GSK currently owns 19.98% of the company which is based in Cambridge, UK and Heidelberg, Germany. ---Subscribe to MedNous to access this article--- Company News Finance, Grants, Deals
